Can Belsomra Be Used Long-Term?
Yes, Belsomra (suvorexant) can be used long-term for chronic insomnia, with evidence supporting safety and efficacy for up to 1 year of continuous nightly use.
Evidence Supporting Long-Term Use
The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline suggests using suvorexant for sleep maintenance insomnia in adults, though this is a WEAK recommendation based on low-quality evidence 1. Importantly, the guideline's weakness reflects limitations in available data rather than concerns about the medication itself 1.
Duration of Safety Data
The FDA label documents that 160 patients received Belsomra for at least one year in clinical trials, with the adverse reaction profile during long-term treatment remaining consistent with the first 3 months 2. A pivotal 1-year randomized controlled trial demonstrated that suvorexant was generally safe and well tolerated over 12 months of nightly treatment 3. The completion rates were reasonable: 62% of suvorexant patients and 63% of placebo patients completed the full year 3.
Real-World Long-Term Use
A Japanese post-marketing surveillance study of 3,248 patients showed a mean administration period of 113 days, with 48.6% of patients continuing treatment at 6 months 4. Notably, among those who discontinued, over 30% stopped due to improvement (mean duration 62 days), suggesting the medication achieved its therapeutic goal 4.
A 2026 meta-analysis specifically examining long-term DORA use (≥6 months) found that suvorexant and other DORAs provided sustained improvements in subjective sleep outcomes at both 6 and 12 months 5.
Safety Profile During Long-Term Use
Adverse Events
- Somnolence is the most common adverse effect (13% vs 3% placebo over 1 year) 3
- Overall adverse event rates were comparable to placebo: 69% with suvorexant vs 64% with placebo over 1 year 3
- Serious adverse events occurred in 5% of suvorexant patients vs 7% of placebo patients 3
- The FDA label confirms adverse reactions during long-term treatment (up to 1 year) were generally consistent with those in the first 3 months 2
Critical Safety Considerations
No evidence of physical dependence or withdrawal: Clinical trials showed no withdrawal symptoms after discontinuation, even after prolonged use 2. The 1-year trial included a 2-month randomized discontinuation phase with abrupt cessation, providing robust evidence against rebound insomnia or withdrawal 3.
Dose-dependent effects: Higher doses (above the recommended 10-20 mg) show increased somnolence and other CNS effects 2. The 2026 meta-analysis noted that higher doses may be less well tolerated long-term 5.
Efficacy Maintained Over Time
The 1-year trial demonstrated sustained efficacy:
- At month 1: suvorexant improved subjective total sleep time by 22.7 minutes more than placebo (p<0.0001) 3
- At month 1: reduced time to sleep onset by 9.5 minutes more than placebo (p=0.0002) 3
The Japanese real-world study showed maintained effects throughout 6 months, with sleep latency reduction from 60 to 50 minutes and total sleep time increase from 300 to 360 minutes 4.
Important Caveats and Monitoring
Populations Requiring Caution
Elderly patients: The FDA label notes elderly patients are at higher risk for falls due to increased drowsiness 2. However, elderly-specific analyses showed suvorexant was effective and well-tolerated over 3 months in patients ≥65 years 6.
Respiratory compromise: Use caution in patients with obstructive sleep apnea or COPD. Belsomra has not been studied in severe OSA or severe COPD 2.
Psychiatric comorbidity: Monitor for worsening depression or suicidal ideation 2. A 2026 case report documented cataplexy-like episodes in a patient with anxiety, suggesting heightened vigilance in those with psychiatric conditions 7.
Rare but Serious Adverse Effects
- Complex sleep behaviors (sleep-walking, sleep-driving): Discontinue immediately if these occur 2
- Sleep paralysis and hypnagogic hallucinations: Explain these potential effects to patients upfront 2
- Cataplexy-like symptoms: Periods of leg weakness can occur, particularly at higher doses 2
Practical Approach to Long-Term Use
- Initiate at appropriate dose: 10 mg for adults, 5 mg for elderly or those on moderate CYP3A inhibitors
- Assess response at 1 month: If inadequate, may increase to 20 mg (15 mg in elderly)
- Monitor for somnolence: Particularly in first weeks and after dose increases
- Periodic reassessment: Evaluate continued need every 3-6 months, though indefinite use is supported by safety data
- No tapering required: Can discontinue abruptly without withdrawal symptoms 2, 3
Comparison to Other Hypnotics
The 2016 American College of Physicians guideline noted that observational studies suggested hypnotics for insomnia were associated with increased risk for dementia, fractures, and major injury 8. However, these studies predominantly examined benzodiazepines and older agents. The orexin receptor antagonist mechanism of suvorexant differs fundamentally from GABA-ergic agents, potentially offering a more favorable long-term safety profile.
The evidence supports that Belsomra can be used safely for chronic insomnia treatment extending to at least 1 year, with maintained efficacy and no evidence of tolerance, dependence, or withdrawal. 2, 3, 5